Tropisetron

Drug Profile

Tropisetron

Alternative Names: ICS 205930; Navoban; Navoban R; Novaban

Latest Information Update: 12 Nov 2016

Price : $50

At a glance

  • Originator Novartis
  • Class Antiemetics; Indoles
  • Mechanism of Action Serotonin 3 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Marketed Nausea and vomiting

Most Recent Events

  • 18 Oct 1999 A study in Japanese patients has been added to the therapeutic trials section
  • 07 Sep 1999 Tropisetron has been approved for paediatric use in the United Kingdom
  • 15 Dec 1998 Launched for Emesis in Argentina (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top